Bioleap
Curated by SignalProvider of computational fragment-based technology for drug discovery
Overview
BioLeap is a drug design company enabled by computational fragment-based design technology. The company's in silico design platform predicts binding affinity based on thermodynamic principles giving drug designers insights to create non-obvious molecules and improve existing molecules. Addresses problems in drug discovery like the limitation of drug-like and patentable leads for important but often difficult biological targets. The company's technology provides a viable alternative to high-throughput screening and traditional shape-based “docking” approaches.
Key facts
- Founded
- 2002
- Headquarters
- Tampa, United States
- Stage
- Sign up to view
- Industry
- Health Technology
Business model
- 3 products and services
- Sign up to view
Contact
- Phone
- Sign up to view